Afatinib a better choice for EGFR-mutated lung cancer in first-line treatment
Patients with EGFR-activating mutations in advanced lung cancer seem to benefit more from afatinib than gefitinib as first-line treatment, researchers report at the first ESMO Asia 2015 Congress in Singapore.
Dec 21, 2015